EP2549276A3 - Couplage covalente et réversible de molecules fonctionelles - Google Patents

Couplage covalente et réversible de molecules fonctionelles Download PDF

Info

Publication number
EP2549276A3
EP2549276A3 EP12189317A EP12189317A EP2549276A3 EP 2549276 A3 EP2549276 A3 EP 2549276A3 EP 12189317 A EP12189317 A EP 12189317A EP 12189317 A EP12189317 A EP 12189317A EP 2549276 A3 EP2549276 A3 EP 2549276A3
Authority
EP
European Patent Office
Prior art keywords
formula
covalent linkage
functional molecules
reversible covalent
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12189317A
Other languages
German (de)
English (en)
Other versions
EP2549276B1 (fr
EP2549276A2 (fr
Inventor
Mark Smith
Stephen Caddick
James Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0913967A external-priority patent/GB0913967D0/en
Priority claimed from GB0913965A external-priority patent/GB0913965D0/en
Priority claimed from GB0914321A external-priority patent/GB0914321D0/en
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to DK15150363.8T priority Critical patent/DK2889624T3/en
Priority to EP15150363.8A priority patent/EP2889624B1/fr
Publication of EP2549276A2 publication Critical patent/EP2549276A2/fr
Publication of EP2549276A3 publication Critical patent/EP2549276A3/fr
Application granted granted Critical
Publication of EP2549276B1 publication Critical patent/EP2549276B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • General Physics & Mathematics (AREA)
EP12189317.6A 2009-08-10 2010-08-09 Couplage covalente et réversible de molecules fonctionelles Active EP2549276B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK15150363.8T DK2889624T3 (en) 2009-08-10 2010-08-09 Reversible covalent bonding of functional molecules
EP15150363.8A EP2889624B1 (fr) 2009-08-10 2010-08-09 Liaison covalente réversible de molécules fonctionnelles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0913967A GB0913967D0 (en) 2009-08-10 2009-08-10 Functionalisation of solid substrates
GB0913965A GB0913965D0 (en) 2009-08-10 2009-08-10 Reversible covalent linkage of functional moieties
GB0914321A GB0914321D0 (en) 2009-08-14 2009-08-14 Thiol protecting group
EP10742867A EP2464972A1 (fr) 2009-08-10 2010-08-09 Liaison colavente réversible de molécules fonctionnelles

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP10742867A Division EP2464972A1 (fr) 2009-08-10 2010-08-09 Liaison colavente réversible de molécules fonctionnelles
EP10742867.4 Division 2010-08-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP15150363.8A Division-Into EP2889624B1 (fr) 2009-08-10 2010-08-09 Liaison covalente réversible de molécules fonctionnelles
EP15150363.8A Division EP2889624B1 (fr) 2009-08-10 2010-08-09 Liaison covalente réversible de molécules fonctionnelles

Publications (3)

Publication Number Publication Date
EP2549276A2 EP2549276A2 (fr) 2013-01-23
EP2549276A3 true EP2549276A3 (fr) 2013-03-20
EP2549276B1 EP2549276B1 (fr) 2015-02-25

Family

ID=42668730

Family Applications (5)

Application Number Title Priority Date Filing Date
EP10744980A Withdrawn EP2464974A1 (fr) 2009-08-10 2010-08-09 Fonctionnalisation de substrats solides
EP10747930.5A Not-in-force EP2464654B1 (fr) 2009-08-10 2010-08-09 Groupement protecteur thiol
EP15150363.8A Active EP2889624B1 (fr) 2009-08-10 2010-08-09 Liaison covalente réversible de molécules fonctionnelles
EP10742867A Withdrawn EP2464972A1 (fr) 2009-08-10 2010-08-09 Liaison colavente réversible de molécules fonctionnelles
EP12189317.6A Active EP2549276B1 (fr) 2009-08-10 2010-08-09 Couplage covalente et réversible de molecules fonctionelles

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EP10744980A Withdrawn EP2464974A1 (fr) 2009-08-10 2010-08-09 Fonctionnalisation de substrats solides
EP10747930.5A Not-in-force EP2464654B1 (fr) 2009-08-10 2010-08-09 Groupement protecteur thiol
EP15150363.8A Active EP2889624B1 (fr) 2009-08-10 2010-08-09 Liaison covalente réversible de molécules fonctionnelles
EP10742867A Withdrawn EP2464972A1 (fr) 2009-08-10 2010-08-09 Liaison colavente réversible de molécules fonctionnelles

Country Status (11)

Country Link
US (6) US20120190579A1 (fr)
EP (5) EP2464974A1 (fr)
JP (3) JP2013501765A (fr)
CN (1) CN102597773B (fr)
AU (2) AU2010283632B2 (fr)
BR (1) BR112012003089A2 (fr)
CA (3) CA2770626A1 (fr)
DK (2) DK2549276T3 (fr)
ES (2) ES2699312T3 (fr)
IL (2) IL218010A (fr)
WO (3) WO2011018612A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
BR112012003089A2 (pt) 2009-08-10 2016-08-16 Ucl Business Plc ligação covalente reversível de moléculas funcionais
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
WO2011124718A1 (fr) 2010-04-09 2011-10-13 Novozymes A/S Dérivés et variants d'albumine
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
BR112014013526A8 (pt) * 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
EP2814512A1 (fr) 2012-02-16 2014-12-24 UCL Business Plc. Lieur clivable par des lysosomes
EP2822597A1 (fr) * 2012-03-09 2015-01-14 UCL Business Plc. Modification chimique d'anticorps
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
CA2890766A1 (fr) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Variants d'albumine
EA201591049A1 (ru) 2012-11-30 2015-09-30 Новартис Аг Способы получения конъюгатов дисульфидсодержащих белков
CN105188766B (zh) 2013-03-15 2019-07-12 瑞泽恩制药公司 生物活性分子、其偶联物及治疗用途
WO2014197871A2 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Conjugués anticorps-médicament, compositions et méthodes d'utilisation correspondantes
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
EP3038624A1 (fr) 2013-08-26 2016-07-06 Regeneron Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des diastéréomères macrolides, leurs procédés de synthèse et leurs utilisations thérapeutiques
WO2015079376A1 (fr) 2013-11-26 2015-06-04 Novartis Ag Procédés de conjugaison oxime à des polypeptide à modification cétone
MA39313B1 (fr) 2014-03-11 2018-12-31 Regeneron Pharma Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
US10406198B2 (en) 2014-05-23 2019-09-10 Novartis Ag Methods for making conjugates from disulfide-containing proteins
CN105294832B (zh) * 2014-08-11 2020-11-06 浙江海洋学院 一种缢蛏活性三肽及其制备方法和应用
KR20230158134A (ko) 2014-10-14 2023-11-17 폴리테릭스 리미티드 Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법
US10342441B2 (en) 2015-02-27 2019-07-09 Qualcomm Incorporated Estimating heart rate by tracking optical signal frequency components
US20160375147A1 (en) 2015-03-27 2016-12-29 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
CN104910312B (zh) * 2015-05-28 2019-03-15 江苏省原子医学研究所 一种提高染料荧光强度的线性聚合物及其制备方法和应用
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
CA2989966C (fr) 2015-08-20 2024-04-30 Albumedix A/S Variants de l'albumine et leurs conjugues
CA3005683A1 (fr) 2015-11-27 2017-06-01 Heidelberg Pharma Research Gmbh Derives de gamma-amanitine
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
EP3222292A1 (fr) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Conjugués d'amanitine
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
WO2018002902A1 (fr) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Conjugués anticorps-médicament et procédés thérapeutiques utilisant ceux-ci
WO2018067331A1 (fr) 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Anticorps bispécifiques anti-muc16-cd3 et conjugués médicament anti-muc16
SG10202102617QA (en) 2016-09-23 2021-04-29 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
SG10202104259RA (en) 2016-11-08 2021-06-29 Regeneron Pharma Steroids and protein-conjugates thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
US11491231B2 (en) * 2017-03-31 2022-11-08 University of Pittsburgh—of the Commonwealth System of Higher Education Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the assembly of morphologically-tunable soft materials
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
JP7220199B2 (ja) 2017-08-07 2023-02-09 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマニチンの新規な合成方法
EP3665173A1 (fr) 2017-08-07 2020-06-17 Heidelberg Pharma Research GmbH Nouveau procédé de synthèse d'amanitines
AU2018335378A1 (en) 2017-09-22 2020-04-09 Heidelberg Pharma Research Gmbh PSMA-targeting amanitin conjugates
KR20200108002A (ko) 2018-01-08 2020-09-16 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 항체-접합체
CA3093083A1 (fr) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugues
EP3773680A1 (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Conjugués d'il-2
CA3097711A1 (fr) 2018-04-30 2019-11-07 Regeneron Pharmaceuticals, Inc. Anticorps et molecules de liaison a l'antigene bispecifiques se liant a her2 et/ou aplp2, conjugues et utilisations associees
EP3790899A1 (fr) 2018-05-09 2021-03-17 Regeneron Pharmaceuticals, Inc. Anticorps anti-msr1 et leurs procédés d'utilisation
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
GB2575793A (en) * 2018-07-20 2020-01-29 Montanuniv Leoben Resin composition suitable for printing and printing methods
CN109293683A (zh) * 2018-09-05 2019-02-01 河南师范大学 一种还原响应型喜树碱二聚体及基于该喜树碱二聚体的还原敏感的药物传递系统
WO2020125546A1 (fr) * 2018-12-17 2020-06-25 荣昌生物制药（烟台）有限公司 Connecteur destiné à être utilisé dans un conjugué médicament anticorps et applications de connecteur
MA54545A (fr) 2018-12-21 2021-10-27 Regeneron Pharma Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
AU2020224136A1 (en) 2019-02-21 2021-09-02 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-MET antibodies and bispecific antigen binding molecules that bind MET
CA3146933A1 (fr) 2019-09-16 2021-03-25 Marcus KELLY Proteines de liaison de met radiomarquees pour imagerie immuno-tep
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
CA3166619A1 (fr) 2020-02-28 2021-09-02 Julian Andreev Molecules bispecifiques de liaison a l'antigene qui se lient a her2, et leurs procedes d'utilisation
JP2023521885A (ja) 2020-04-16 2023-05-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ディールス－アルダーコンジュゲーション方法
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
MX2023000544A (es) 2020-07-13 2023-02-13 Regeneron Pharma Conjugados de proteina-farmaco que comprenden analogos de camptotecina y metodos de uso de los mismos.
KR20230070337A (ko) 2020-09-14 2023-05-22 리제너론 파마슈티칼스 인코포레이티드 Glp1 펩티도미메틱을 포함하는 항체-약물 접합체 및 이의 용도
CN116406379A (zh) 2020-10-22 2023-07-07 瑞泽恩制药公司 抗fgfr2抗体和其使用方法
CN114031719B (zh) * 2021-11-26 2023-11-07 珠海宏昌电子材料有限公司 双马来酰亚胺-三嗪树脂及其制备方法和应用
US20230287138A1 (en) 2022-01-12 2023-09-14 Regneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
CN114377723B (zh) * 2022-01-22 2022-12-13 海南大学 一种二氧化钛及其可见光催化产氢
WO2023173132A1 (fr) 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. Conjugués anticorps-médicament anti-glp1r comprenant des peptidomimétiques de glp1 et leurs utilisations
WO2024020164A2 (fr) 2022-07-21 2024-01-25 Firefly Bio, Inc. Agonistes du récepteur des glucocorticoïdes et leurs conjugués
WO2024081151A1 (fr) * 2022-10-11 2024-04-18 Ohio State Innovation Foundation Détection d'un amphiphile à l'aide d'une inspection visuelle d'un substrat modifié par un ligand

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA667583A (en) * 1963-07-30 Druey Jean Tetrahydro-dioxopyridazines and process for their preparation
DE19843873A1 (de) * 1998-09-25 2000-03-30 Univ Halle Wittenberg Verfahren zur Bestimmung von Proteaseaktivitäten auf Zelloberflächen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861093A (en) 1956-09-24 1958-11-18 Eastman Kodak Co Reaction products of dialkyl phosphorothiolothionates and mucohalic acids
BE725964A (fr) 1967-12-23 1969-05-29
DE2032709A1 (en) 1970-07-02 1972-01-20 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen 2-halo-3-mercapto-maleicaldehydeacids as photo-hardeners - from mucohaloacids and mercaptans with bases in inert solvents
JPS5440556B2 (fr) 1973-03-13 1979-12-04
GB1544686A (en) 1977-07-12 1979-04-25 Ici Ltd Disperse anthraquinone dyestuffs
DE3513715A1 (de) 1985-04-17 1986-10-23 Bayer Ag, 5090 Leverkusen Polycarbonate mit dichlormaleinimid-endgruppen, ihre herstellung und modifizierung
US4680272A (en) 1985-10-23 1987-07-14 University Of California Method for detecting molecules containing amine or thiol groups
JPS63145282A (ja) 1986-12-08 1988-06-17 Taiyo Yakuhin Kogyo Kk ピリダジン誘導体
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
PT100941A (pt) 1991-10-11 1993-10-29 Ciba Geigy Ag Herbicidas a base de eteres ou tioeteres pirimidinilicos ou triazinilicos, e processo para a sua preparacao
US5414074A (en) 1992-09-25 1995-05-09 University Of Michigan Synthesis of C-glycosylated compounds with the use of a mild, iodine-catalyzed reaction
DE4310141A1 (de) 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
GB9801210D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
US7442764B2 (en) 1999-06-07 2008-10-28 Mirns Bio Corporation Reversible modification of amine-containing compounds
GB2352085A (en) 1999-07-15 2001-01-17 Univ Bristol Integrated semiconductor optical devices
DE10032335A1 (de) 2000-07-04 2002-01-17 Cognis Deutschland Gmbh Dimethylbenzol-Derivate
JP2004531700A (ja) 2001-02-05 2004-10-14 グラフィニティー、ファーマスーティカルス アーゲー 低親和性スクリーニング法
ES2330089T3 (es) 2001-08-17 2009-12-04 Mitsui Chemicals Agro, Inc. Derivado de 3-fenoxi-4-piridazinol y composicion herbicida que lo contiene.
JP2005539223A (ja) * 2002-09-13 2005-12-22 ポール コーポレイション クロマトグラフィーの吸着剤およびバイオチップアレイのための混合モード固体基材の調製および使用
US20090074885A1 (en) 2003-09-08 2009-03-19 Roche Madison Inc. Reversible Hydrophobic Modification of Drugs for Improved Delivery to Cells
EP1722781A4 (fr) 2004-02-22 2010-07-21 Us Gov Health & Human Serv Inhibiteurs de phosphatase antitumoraux a base de maleiimide
CN1774451A (zh) 2004-05-13 2006-05-17 横滨橡胶株式会社 马来酰亚胺封端橡胶和用所述马来酰亚胺封端橡胶制备的可固化组合物
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
US20070248950A1 (en) 2006-04-19 2007-10-25 Analytical Biological Services, Inc. Supported polydiacetylene 3-D arrays for flourescent or phosphorescent detection
GB0716783D0 (en) 2007-08-29 2007-10-10 Ucl Business Plc New Process
EP2323678B1 (fr) 2008-08-07 2016-03-23 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
EP2320923B1 (fr) 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Analogues tronqués de polypeptide insulinotrope glucose-dépendant
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
BR112012003089A2 (pt) 2009-08-10 2016-08-16 Ucl Business Plc ligação covalente reversível de moléculas funcionais
EP2814512A1 (fr) * 2012-02-16 2014-12-24 UCL Business Plc. Lieur clivable par des lysosomes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA667583A (en) * 1963-07-30 Druey Jean Tetrahydro-dioxopyridazines and process for their preparation
DE19843873A1 (de) * 1998-09-25 2000-03-30 Univ Halle Wittenberg Verfahren zur Bestimmung von Proteaseaktivitäten auf Zelloberflächen

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AL-HOLLY M M ET AL: "Synthesis of glucosylthiomaleimides", DIE PHARMAZIE, vol. 34, no. 10, 1979, pages 645 - 646, XP008157981 *
AUGUSTIN M ET AL: "SYNTHESE VON N-DICHLORMALEOYL-AMINOSAEUREN UND -PEPTIDEN", JOURNAL FÜR PRAKTISCHE CHEMIE, vol. 327, no. 5, 1985, pages 857 - 864, XP000671367 *
BALONIAK S ET AL: "Ipso and cine substitution of bromine in the 4-bromo- and 5-bromopyridinazine-3,6-dione derivatives. Part II. Reactions with thiols", POLISH JOURNAL OF CHEMISTRY, vol. 66, no. 6, 1 January 1992 (1992-01-01), pages 935 - 941, XP008157974 *
C GAINA ET AL: "Poly(Urethane-Urea) Varnishes Containing Tributyltin Groups", JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS, vol. 19, no. 2, 19 November 2008 (2008-11-19), pages 157 - 165, XP019681364 *
D. M. LYNCH ET AL: "Reactions of dichloromaleimides with alcohols, phenols, and thiols", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 9, no. 5, 1972, pages 1027 - 1032, XP055044117 *
FONSECA A P ET AL: "A Novel Synthesis of Arcyriaflavin-A", TETRAHEDRON LETTERS, vol. 36, no. 15, 1995, pages 2689 - 2692, XP004028284 *
LOREY S ET AL: "Additions and Corrections:Transcellular proteolysis demonstrated by novel cell surface-associated substrates of dipeptidyl peptidase IV (CD26)", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 43, 2002, pages 41294, XP002604986 *
LOREY S ET AL: "Transcellular proteolysis demonstrated by novel cell surface-associated substrates of dipeptidyl peptidase IV (CD26)", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 36, 2002, pages 33170 - 33177, XP002601595 *
P CONDORELLI ET AL: "Synthesis of 2,3-diazaphenothiazines II. N-Methyl derivatives of 1,4-dioxo-1,2,3,4-tetrahydro-2,3-diazaphenothiazine", BOLLETTINO DELLE SEDUTE DELLA ACCADEMIA GIOENIA DI SCIENZE NATURALI IN CATANIA, vol. 9, no. 4, 1967, pages 242 - 251, XP008159970 *
S BALONIAK AND A OSTROWICZ: "Ipso and cine substitution of bromine in the 4-bromo- and 5-bromopyridazine-3,6-dione derivatives. Part I. Reactions with sodium thiolates", POLISH JOURNAL OF CHEMISTRY, vol. 61, no. 5-6, 1991, pages 1085 - 1090, XP008159971 *
SMITH M E B ET AL: "Protein modification, bioconjugation, and disulfide bridging using bromomaleimides.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 6, 17 February 2010 (2010-02-17), pages 1960 - 1965, XP002601596 *
TEDALDI L M ET AL: "Bromomaleimides: new reagents for the selective and reversible modification of cysteine.", CHEMICAL COMMUNICATIONS, no. 43, 21 November 2009 (2009-11-21), pages 6583 - 6585, XP002601597 *

Also Published As

Publication number Publication date
EP2549276B1 (fr) 2015-02-25
CA2770617C (fr) 2018-02-20
CA2770626A1 (fr) 2011-02-17
US20160176942A1 (en) 2016-06-23
CA2770617A1 (fr) 2011-02-17
US10933142B2 (en) 2021-03-02
WO2011018613A1 (fr) 2011-02-17
BR112012003089A2 (pt) 2016-08-16
DK2549276T3 (en) 2015-06-08
DK2889624T3 (en) 2018-12-10
US10174094B2 (en) 2019-01-08
IL218010A (en) 2016-05-31
WO2011018612A3 (fr) 2011-04-14
AU2010283632A1 (en) 2012-03-08
US20200108150A1 (en) 2020-04-09
AU2016262736B2 (en) 2018-05-10
WO2011018612A2 (fr) 2011-02-17
EP2889624A3 (fr) 2015-09-30
AU2016262736A1 (en) 2016-12-15
AU2010283632B2 (en) 2016-08-25
JP5954789B2 (ja) 2016-07-20
EP2464972A1 (fr) 2012-06-20
EP2549276A2 (fr) 2013-01-23
EP2889624B1 (fr) 2018-10-03
CN102597773B (zh) 2015-07-15
CN102597773A (zh) 2012-07-18
EP2464974A1 (fr) 2012-06-20
US20190142950A1 (en) 2019-05-16
WO2011018611A1 (fr) 2011-02-17
US9295729B2 (en) 2016-03-29
EP2889624A2 (fr) 2015-07-01
JP2013501766A (ja) 2013-01-17
IL245506A (en) 2017-09-28
JP2013501764A (ja) 2013-01-17
IL218010A0 (en) 2012-04-30
JP2013501765A (ja) 2013-01-17
US10548982B2 (en) 2020-02-04
ES2537623T3 (es) 2015-06-10
US20120190814A1 (en) 2012-07-26
AU2010283632A2 (en) 2012-03-08
EP2464654A2 (fr) 2012-06-20
ES2699312T3 (es) 2019-02-08
IL245506A0 (en) 2016-06-30
US20120190124A1 (en) 2012-07-26
US20120190579A1 (en) 2012-07-26
EP2464654B1 (fr) 2014-10-08
CA2770620A1 (fr) 2011-02-17

Similar Documents

Publication Publication Date Title
EP2549276A3 (fr) Couplage covalente et réversible de molecules fonctionelles
WO2013093720A3 (fr) Composés antidiabétiques
EP2639228A3 (fr) Composés cyanoéthylamino aryloazol-2-yl, procédé de fabrication et leur procédé d'utilisation
EP2374481A3 (fr) Nouveaux réactifs et procédé pour conjuguer des molécules biologiques
EP1980593A3 (fr) Composés de colorants pour encres de changement de phase
WO2009043027A3 (fr) Formes tentaculaires de polyoxazoline activée et leurs procédés de synthèse
EP2443926A3 (fr) Analogues de la cyclopamine
EP2277595A3 (fr) Composés pour potentialiser l'immunité
WO2012059873A3 (fr) Composés antidiabétiques
WO2007144709A3 (fr) DÉRIVÉS de LEPTOMYCINE
EP2388256A3 (fr) Procédé de préparation de benzofuranes
WO2007113224A3 (fr) Procédé de conjugaison
EP2105451A3 (fr) Polymère contenant un groupe de nitrile et son procédé de synthèse, composition contenant le polymère contenant un groupe de nitrile, et stratifié
EP2508523A3 (fr) Polymorphes de dasatinib et leur procédé de préparation
EP2431367A3 (fr) Composés cycliques condensés comme modulateurs du recepteur GPR40
WO2009158606A3 (fr) Structure, synthèse, et applications pour oligo phénylène éthynylènes
FR2887555B1 (fr) Procede de preparation d'une coupe diesel par oligomerisation
WO2008009831A3 (fr) Derives de cyclodextrines amphiphiles
WO2006032893A3 (fr) Derives de trityle pour spectrometrie de masse amelioree
AR060174A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
EP2550965A3 (fr) Dérivés de céramide pour le traitement de la polykystose rénale
EP1985667A3 (fr) Composés de coloration du type pyrazolone-azo
WO2010023670A3 (fr) Procédés permettant de fixer par covalence un polymère à un résidu de méthionine dans des protéines et des peptides
AR062504A1 (es) Procedimientos para preparar acidos d,l-2hidroxi-4-alquiltiobutiricos
WO2007103221A3 (fr) Procede ameliore pour la preparation de l'armodafinil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2464972

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/58 20060101ALI20130214BHEP

Ipc: G01N 33/533 20060101AFI20130214BHEP

Ipc: G01N 33/543 20060101ALI20130214BHEP

Ipc: G01N 33/535 20060101ALI20130214BHEP

17P Request for examination filed

Effective date: 20130920

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

17Q First examination report despatched

Effective date: 20131118

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140904

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2464972

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010022737

Country of ref document: DE

Effective date: 20150409

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 712408

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150415

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MEYER AND KOLLEGEN, CH

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150601

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2537623

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150610

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 712408

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150225

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150525

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150625

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150526

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010022737

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20151126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100809

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20190826

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20190822

Year of fee payment: 10

Ref country code: FI

Payment date: 20190820

Year of fee payment: 10

Ref country code: DK

Payment date: 20190822

Year of fee payment: 10

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20200831

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20200901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200901

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230831

Year of fee payment: 14

Ref country code: IE

Payment date: 20230821

Year of fee payment: 14

Ref country code: GB

Payment date: 20230816

Year of fee payment: 14

Ref country code: ES

Payment date: 20230918

Year of fee payment: 14

Ref country code: CH

Payment date: 20230902

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230822

Year of fee payment: 14

Ref country code: DE

Payment date: 20230822

Year of fee payment: 14